BETERCAL Softgel Capsules
Calcitriol 0.25 mcg + Calcium Carbonate 500 mg + Zinc 7.5 mg
This formulation combines Calcitriol, calcium and Zinc.
Calcitriol is important for the absorption of calcium from the stomach and for the functioning of calcium in
the body. The known sites of action of Calcitriol are intestine, bone, kidney and parathyroid gland. In bone,
Calcitriol in conjunction with parathyroid hormone stimulates resorption of calcium; and in the kidney,
calcitriol increases the tubular reabsorption of calcium.
Calcium plays a critical role in the body. It is essential for normal functioning of nerves, cells, muscle and bone.
Calcium prevents bone loss and is associated with a modest reduction in fracture risk. Calcium and vitamin D
preparations are used to prevent or to treat calcium deficiency.
Adequate Zinc is required for normal growth and tissue repair. Urinary elimination of Zinc is increased in
osteoporotic women. Zinc depletion is shown to diminish the response of oral VIT. D 3 when administered
orally. Supplementary Zinc not only improves VIT. D 3 response but also helps to arrest bone loss in old
Betercal is indicated in :
1.) Management of hypocalcaemia in patients undergoing dialysis for chronic renal failure. It has been shown
to significantly reduce elevated parathyroid hormone (PTH) levels. Reduction of PTH has been shown to
result in an improvement in renal osteodystrophy
2.) Post-menopausal osteoporosis.
3.) Hypocalcaemia in hypoparathyroidism
5.) Vitamin D dependent rickets
6.) Renal tubular osteocalcaemia
7.) Sporadic and oncogenic hypophosphatemic osteomalacia
8.) X-linked hypophosphatemic osteomalacia
9.) Osteomalacia in Malabsorption syndrome
10.) Hypocalcaemia and hypomagnesaemia after small bowel resection
11.) Osteoporosis in males
DOSAGE AND ADMINISTRATION
The optimal dose must be carefully determined for each patient. The recommended initial dose is one capsule
of Betercal daily. If a satisfactory response in the biochemical parameters and clinical manifestations of the
disease state is not observed, the dose may be increased by an increment of 1-2 caps at two to four week
intervals. In patients undergoing dialysis, the dose may be increased by an increment of 1 cap at 4 to 8 – week
intervals. During this titration period, serum calcium and phosphorus levels should be obtained at least twice
weekly and if hypercalcaemia is noted, the drug should be immediately discontinued until normocalcaemia
ensues. In patients undergoing dialysis, phosphorus magnesium and alkaline phosphatase should be
determined periodically. Patients should be informed the symptoms of hypercalcaemia.